AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS
Executive Summary
The partial clinical hold placed on a combination trial of AstraZeneca’s PD-L1 inhibitor durvalumab and CTLA-4 inhibitor tremelimumab could be a portent of problems for Bristol-Myers Squibb’s PD-1/CTLA-4 combination trials – or it could be related to the head and neck cancer setting.
You may also be interested in...
Pfizer’s Avelumab Poised For Speedy Review By FDA
Avelumab could be the fourth PD-1/L1 inhibitor to reach the market now that the US FDA has accepted Pfizer’s and Merck KGaA’s BLA for priority review in the treatment of metastatic Merkel cell carcinoma.
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
The latest drug development news and highlights from our FDA Performance Tracker.
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.